Hepatocellular Carcinoma Research Reagents | AFP, GPC3, PD-L1 Antibodies

Hepatocellular Carcinoma — Disease Background

Hepatocellular carcinoma (HCC) is the sixth most diagnosed cancer and the third leading cause of cancer death globally. Chronic hepatitis B (HBV) and hepatitis C (HCV) infection, alcohol-related liver disease, and metabolic dysfunction-associated steatohepatitis (MASH) are the principal etiological factors, with HCC developing almost exclusively on a background of cirrhosis.

The treatment landscape has evolved from sorafenib monotherapy to combination immunotherapy — atezolizumab plus bevacizumab (IMbrave150) is now first-line standard of care. Emerging combinations include durvalumab plus tremelimumab and lenvatinib-based regimens. GPC3-targeted approaches (CAR-T, bispecific antibodies) represent promising HCC-specific immunotherapy strategies.

Research Use Only (RUO)

Not intended for diagnostic or therapeutic procedures.

Hepatocellular carcinoma pathogenesis pathway — WNT, VEGF, PD-1/PD-L1 signaling

Fig. 1 Major pathogenic pathways in Hepatocellular Carcinoma

Key Research Targets

AFP (Alpha-Fetoprotein) — AFP is the most widely used serum biomarker for HCC surveillance in cirrhotic patients. Anti-AFP antibodies and recombinant AFP proteins support immunoassay development, IHC tissue confirmation, and AFP-L3 fraction studies for improved diagnostic specificity distinguishing HCC from benign liver disease.

GPC3 (Glypican-3) — GPC3 is a cell-surface oncofetal proteoglycan highly expressed in HCC but absent in normal adult hepatocytes. Anti-GPC3 antibodies enable IHC-based diagnosis (differentiating HCC from cholangiocarcinoma), flow cytometric analysis, and emerging GPC3-targeted CAR-T cell and bispecific antibody therapeutic research.

VEGF / VEGFR2 — HCC is a highly vascularized tumor dependent on VEGF-driven angiogenesis. Anti-VEGF antibodies and recombinant VEGFR2 proteins support angiogenesis research, bevacizumab combination therapy studies, and VEGF-mediated immunosuppression characterization in the HCC tumor microenvironment.

PD-L1 (CD274) — PD-L1 expression in HCC tumor and microenvironment cells correlates with response to atezolizumab-bevacizumab. Anti-PD-L1 antibodies support expression profiling, combined positive score (CPS) validation, and functional blocking assays for checkpoint combination therapy optimization in liver cancer.

References

1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905. DOI

2. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. DOI

3. The Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169(7):1327-1341. DOI

4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390. DOI

5. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8):EVIDoa2100070. DOI